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We recently reported an association between low DNA repair capacity, measured through the host-cell reactivation assay, and
melanoma risk in subjects with dysplastic naevi or low tanning ability. We investigated the genetic basis for these findings by analysing
the Asp312Asn and Lys751Gln polymorphisms of the XPD (ERCC2) DNA repair gene in the same subjects. Similar to our previous
report, no significant association between XPD polymorphisms and melanoma risk was found in 176 melanoma cases and 177
controls (odds ratio (OR)¼1.5, 95% confidence interval (CI)¼0.9–2.5 for 312Asn; OR¼1.3, 95% CI¼0.8–2.1 for 751Gln,
adjusted for age, gender, dysplastic naevi and pigmentation characteristics). However, XPD variants were associated with increased
risk in older (450 years) subjects (OR¼3.4, 95% CI¼1.6–7.3 for 312Asn; OR¼2.3, 95% CI¼1.1–4.9 for 751Gln). The 751Gln
allele was associated with elevated melanoma risk among subjects without dysplastic naevi (OR¼2.6, 95% CI¼1.1–6.4). Subjects
with low tanning ability and XPD variants exhibited a nonsignificant increase of melanoma risk (OR¼2.3, 95% CI¼0.7–7.0 for
312Asn; OR¼3.0, 95% CI¼1.0–8.8 for 751Gln). DNA repair capacity was slightly decreased in subjects carrying 751Gln alleles.
XPD variants may modify melanoma risk in subjects with specific host characteristics, such as older age, lack of dysplastic naevi or low
tanning ability.
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Between 1940 and 2000, descriptive studies documented a
progressive worldwide rise in the incidence of cutaneous
malignant melanoma. Melanoma risk increases with age
(Kosary et al, 1996; Gilchrest et al, 1999) and other risk factors,
such as sunlight exposure (IARC, 1992), particularly inter-
mittent (Gilchrest et al, 1999), family history of melanoma,
dysplastic naevi or atypical naevi, number of naevi, skin sen-
sitivity to sun, freckling, fair hair, eye and skin colour (Tucker et al,
1997; Landi et al, 2001). Individuals with inherited defects in
nucleotide excision repair (eg, patients with xeroderma pigmento-
sum, XP) have low repair of UV-induced DNA lesions and are at
extremely high risk of skin cancers, including melanoma (Berne-
burg and Lehmann, 2001). In healthy subjects, polymorphisms
in DNA repair genes may be associated with altered DNA
repair capacity and susceptibility to cancer (Benhamou and
Sarasin, 2002).
The XP complementation group D (XPD, also known as ERCC2)
protein, a subunit of the Transcription Factor IIH (TFIIH), is
involved in DNA unwinding during DNA repair and initiation of
basal transcription (Berneburg and Lehmann, 2001). Several single
nucleotide polymorphisms (SNPs) in XPD gene exons have
been identified (Benhamou and Sarasin, 2002). The nonsilent
variants at codons 312 (exon10, G4A, Asp312Asn) and 751
(Exon23, A4C, Lys751Gln) are amenable to investigation in
epidemiological studies in Caucasians, given their high frequency
(Benhamou and Sarasin, 2002). The XPD 751Gln variant sub-
stantially modifies the amino-acid electronic configuration in a
domain important for the interaction with the helicase
activator p44 and may produce the most relevant change in
XPD function (Coin et al, 1998; Benhamou and Sarasin, 2002).
Aging has been associated with depressed in situ repair of
UV-specific DNA lesions in the skin of subjects carrying
the XPD variants 312Asn and 751Gln (Hemminki et al,
2001), who may therefore be at higher risk for cancer at an older
age (Dybdahl et al, 1999; Sturgis et al, 2000). We recently
showed that specific host characteristics, such as presence of
dysplastic naevi and low tanning ability, modify the risk of
melanoma associated with low DNA repair capacity (Landi et al,
2002). We report here on (i) the association between the
Asp312Asn and Lys751Gln XPD polymorphisms and cutaneous
malignant melanoma risk, (ii) the effect modification of age,
presence of dysplastic naevi and tanning ability, and (iii) the
association between XPD polymorphisms and DNA repair
capacity, in the same subjects.
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Study subjects
From December 1994 to January 1999, we recruited 183 (87 male
and 96 female) cases with incident nonfamilial cutaneous
malignant melanoma (of any stage) and 179 (89 male and 90
female) controls between the ages of 17 and 77 years at the
Dermatology Unit of the Bufalini Hospital in Cesena, Italy, as
previously described (Landi et al, 2001, 2002). The Hospital
examined approximately 85% of all the melanoma patients of the
Northern Marche and Southern Romagna areas, from which all
study subjects came from (Landi et al, 2002). Approximately 95%
of the cases and 83% of the controls agreed to participate in the
study. Control subjects, frequency-matched to the cases by decade
of age and gender, were recruited among spouses or close friends
of the cases (n¼134), outpatients with minor accidental trauma
(n¼14) and healthy volunteers from the hospital personnel
(n¼34). The exclusion of the trauma patients and/or the hospital
personnel volunteers from the analysis did not change the results.
We obtained the study approval from the Bufalini Hospital’s
Ethical Committee and informed written consent from all
participants. Trained interviewers administered a standardised
in-person questionnaire and a single dermatologist examined all
study subjects. The tanning ability was ascertained through the
following question: ‘After repeated and prolonged exposure to
sunlight, your skin (1) becomes very tanned, (2) becomes medium
tanned, (3) becomes hardly tanned, (4) has a tendency to peel, or
(5) has absolutely no change’.
Because no one selected choice 4 and only three selected choice
5, the answers were categorised into three groups: high tanning
response (choice 1), medium tanning response (choice 2), and low
tanning response (choices 3 and 5) (Landi et al, 2002).
An expert oncologist, blinded to melanoma status, assessed
dysplastic naevus diagnoses and naevus counts in standardised
photographs of the subjects’ backs, as previously described (Landi
et al, 2002). In total, 15 cases and 15 controls had either no
photographs or uncertain dysplastic naevus diagnosis. A three-
category variable (dysplastic naevi, no dysplastic naevi, unknown/
uncertain dysplastic naevi) was used in the statistical models.
Naevi and dysplastic naevi tend to disappear with age, making
their diagnosis difficult to assess in older individuals (Tucker et al,
1997). We, therefore, classified all subjects (47 cases and 28
controls) older than 60 years of age as with uncertain dysplastic
naevus status (Landi et al, 2002). However, the use in the analysis
of dysplastic naevus data from these older subjects did not change
the results.
DNA extraction and XPD genotyping
Genomic DNA was extracted from 1–2 10
6 cryopreserved
lymphocytes. We used the Nucleon Extraction and Purification
kit (Amersham LIFE SCIENCE, UK), following the manufacturer’s
instructions. Using lymphocyte DNA as template, we genotyped
the Asp312Asn SNP using a Taqman 50-nuclease assay and the
Lys751Gln with a PCR–RFLP assay. Asp312Asn was genotyped in
a 25-ml reaction containing Taqman Universal Master Mix
(Applied Biosystems, Foster City, CA, USA) run on an ABI 7700
Sequence-Detection system (Applied Biosystems, Foster City, CA,
USA). The reaction included the primers 50-CTCCgCAggATCAAA-
gAgACA-30 and 50-TCTgCgAggAgACgCTATCA-30 at 900nM, and
the probes 50-VIC-CCgTgCTgCCCgACgAAgT-TAMRA-30 recognis-
ing the Asp(G) allele and 50-6FAM-CCgTgCTgCCCAACgAAgTg-
TAMRA-30 recognising the Asn(A) allele, at 200nM and 10ng of
genomic DNA as template. No template controls and samples
verified to have all three possible genotypes were included with
each reaction plate. Genotypes for Asp312Asn were successfully
determined in 164 cases and 172 controls. The Lys751Gln
polymorphic site was amplified using the primers 50-
ATCCTgTCCCTACTggCCATTC-30 and 50-TgTggACgTgACAgTgA-
gAAAT-30 in 50ml polymerase chain reaction (PCR) reactions
containing: 10mM Tris-HCl (pH 8.8 at 251C), 1.5mM MgCl2,
50mM KCl, 0.1% Triton X-100, 0.2mM each deoxynucleotide
triphosphate, 20pmoles of each primer, 2U of Taq DNA
Polymerase Dynazyme (Finzymes, ESPOO, Finland) and
50–100ng of genomic DNA. The cycling conditions were: initial
denaturation at 951C for 3min, 30 cycles of denaturation at 941C
for 45s, primer annealing at 601C for 45s, primer extension at
721C for 1min and final extension at 721C for 5min. The
PCR product was digested with 10–15U of PstI enzyme (Promega,
Madison, WI, USA) in a 25-ml-reaction mixture for 2h at 371C,
as suggested by the manufacturer, and separated on a 2% agarose
gel. In addition to a PstI site away from the polymorphism that
serves as internal control for digestion, the Lys(A) allele has a
second PstI restriction site. The three possible genotypes are
defined by three distinct banding patterns: AA (100- and 224-bp
fragments), AC (66-, 100-, 158- and 224-bp fragments) and CC
(66-, 100- and 158-bp fragments). Genotypes for Lys751Gln were
successfully determined in 176 cases and 177 controls. For quality
control purposes, DNA samples from 335 subjects who had been
tested for the Lys751Gln polymorphisms were genotyped by
an independent laboratory. Between-laboratory agreement was
equal to 97.3%.
Host-cell reactivation (HCR) assay
We measured DNA repair capacity in cryopreserved lymphocytes
by the CAT-gene based HCR assay, as previously described (Athas
et al, 1991; Landi et al, 2002). CAT activity41000c.p.m. in
unirradiated cells is required to measure accurately the DNA repair
capacity with a signal-to-noise ratio at least two-fold higher than
the background level (200c.p.m.) in cells with irradiated plasmids
(Landi et al, 2002). DNA repair capacity measured in lymphocytes
with baseline CAT activityo1000c.p.m. (44 cases and 32 controls)
was not considered in the analysis.
All laboratory analyses were performed blinded to the case
status.
Statistical analysis
We calculated adjusted odds ratios (ORs) and 95% confidence
intervals (CIs) by unconditional multiple logistic regression
models that included the matching variables (i.e., age and gender),
presence of dysplastic naevi, skin colour, tanning ability and
eye colour as independent variables. Because of the relatively small
number of subjects with the homozygous variant genotypes,
we used two-category variables (consensus vs heterozygous/
homozygous) in logistic regression analysis. The models
with three-category variables were not substantially different from
the models with two-category variables (PX0.17, likelihood
ratio tests). We used the likelihood ratio test to test for
interactions, which were also evaluated using a case-only analy-
sis (Yang et al, 1997). The case-only approach confirmed the
results of the case–control analysis. Here, we report the analy-
sis based on cases and controls. Age was a matching variable and,
therefore, we could not estimate its main effect on melanoma
risk in the logistic models including the interaction between
age and the XPD polymorphisms. Hardy–Weinberg equilibrium
was tested using the asymptotic Pearson’s w
2-test. We used
the Fisher’s exact test to compare proportions and the Spearman’s
rank correlation statistics to assess linear correlation between
variables. All statistical tests were two-sided. The Stata 7.0
statistical package was used for all analyses (Stata Corporation,
College Station, TX, USA).
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Distribution of the XPD polymorphisms
Frequencies of XPD 312Asn and 751Gln alleles were 0.396 and
0.403, respectively, in cases, and 0.398 and 0.427, respectively, in
controls. The distribution of both polymorphisms among controls
was consistent with the Hardy–Weinberg equilibrium (P¼0.30 for
Asp312Asn and P¼0.81 for Lys751Gln), also when the subjects
were subdivided in age, dysplastic naevus status or tanning ability
categories. Consistently with previous reports (Butkiewicz et al,
2001; Zhou et al, 2002), carriers of the 312Asp/Asp genotype
tended to have the 751Lys/Lys genotype (test for the association
between Asp312Asn and Lys751Gln genotypes: P¼2.1 10
 24 in
controls, and P¼1.1 10
 22 in cases).
In controls, XPD genotypes were not associated with age, gender
or the strongest risk factors for melanoma in this population
(Landi et al, 2001), that is, eye colour, skin colour, tanning ability
to prolonged and repeated sun exposure, and presence of
dysplastic naevi (Table 1). In addition, XPD genotypes were not
associated with hair colour, freckling, skin response to 30min of
sun exposure, naevus number, lifetime number of severe sunburns,
and lifetime or childhood cumulative hours of sun exposure
during vacation (data not shown).
XPD polymorphisms and melanoma risk
Overall, the XPD polymorphisms were not significantly associated
with melanoma risk (Table 2). Subjects with at least one 312Asn
variant allele had an OR for melanoma of 1.5 (95% CI¼0.9–2.5,
adjusted for age, gender, presence of dysplastic naevi, skin colour,
tanning ability, and eye colour) compared with individuals with
the 312Asp/Asp genotype. Subjects with at least one 751Gln variant
allele had an OR of 1.3 (95% CI¼0.8–2.1) in comparison with
subjects carrying the 751Lys/Lys genotype.
Upon dividing the subjects into two age groups, we found
an increased melanoma risk for older subjects carrying variant
alleles (Table 2). Among subjects with ageX50 years, those
with at least one 312Asn allele had an OR of 3.4 (95% CI
¼1.6–7.3). Subjects with the 751Gln variant had OR¼2.3 (95%
CI¼1.1–4.9). In subjects o50 years of age, the XPD variant
alleles were not associated with melanoma (OR¼0.7, 95%
CI¼0.4–1.5 for 312Asn; OR¼0.7, 95% CI¼0.4–1.5 for 751Gln).
The relative odds due to the XPD variants were significantly
higher in older subjects (P¼0.004 for 312Asn; P¼0.03 for
751Gln). We used the 50-years cutoff to define the age categories
in order to compare our results with those reported in previous
studies (Sturgis et al, 2000; Hemminki et al, 2001). We found
similar results using the actual median age of all the subjects
(48 years) or the median age of the controls (45 years) (data not
shown).
After the subjects were stratified according to the presence of
dysplastic naevi (Table 2), individuals without dysplastic naevi and
with the 751Gln/Lys or 751Gln/Gln genotypes showed an increased
melanoma risk (OR¼2.6, 95% CI¼1.1–6.4) compared to those
without dysplastic naevi and with the 751Lys/Lys genotype. Among
subjects without dysplastic naevi, the association between the XPD
polymorphism and melanoma risk appeared limited to older
subjects. When we repeated the analysis in subjects who were 50
years of age or older, having variant alleles at codon 751 was
associated with the highest risk of melanoma among individuals
without dysplastic naevi (OR¼13.9, 95% CI¼1.4–136.3). Among
Table 1 Characteristics of cases and controls by XPD Asp312Asn and Lys751Gln polymorphisms
XPD 312 XPD 751
Case Control Case Control
Asp/Asp
(G/G)
Asp/Asn
(G/A)
Asn/Asn
(A/A)
Asp/Asp
(G/G)
Asp/Asn
(G/A)
Asn/Asn
(A/A)
Lys/Lys
(A/A)
Lys/Gln
(A/C)
Gln/Gln
(C/C)
Lys/Lys
(A/A)
Lys/Gln
(A/C)
Gln/Gln
(C/C)
n¼52 n¼94 n¼18 n¼59 n¼89 n¼24 n¼58 n¼94 n¼24 n¼59 n¼85 n¼33
Age (years)
17–49 31 43 6 28 58 16 34 42 9 30 54 21
50–77 21 51 12 31 31 8 24 52 15 29 31 12
Gender
Male 28 41 9 30 43 12 34 37 13 33 40 16
Female 24 53 9 29 46 12 24 57 11 26 45 17
Eye colour
a
Dark 13 27 2 19 38 11 19 22 4 20 36 17
Medium 24 54 12 33 42 10 27 55 16 32 40 13
Light 15 13 4 7 8 3 12 17 4 7 8 3
Skin colour
Dark/medium 22 43 6 37 62 16 26 41 9 41 56 23
Light 29 51 12 22 27 8 31 53 15 18 29 10
Tanning ability to prolonged sun exposure
High/medium 36 57 10 51 71 21 41 54 16 47 70 29
Low 15 33 8 8 15 2 16 37 7 11 11 4
Dysplastic naevi
b
No 12 32 8 29 60 14 9 34 12 33 52 20
Yes 23 27 5 11 11 6 26 29 4 10 14 5
aDark – black or dark brown. Medium – light brown, brown-green, green or blue-green. Light – light blue, dark blue or grey.
bSubjects older than 60 years of age were
considered as with uncertain dysplastic naevus status. The total number of subjects may vary across variables due to missing values.
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751Gln variant allele did not show a different risk (OR¼0.6, 95%
CI¼0.2–1.6) from those with the 751Lys/Lys genotype. The effect
of the 751Gln variant was significantly higher among subjects
without dysplastic naevi in comparison with subjects with
dysplastic naevi (P¼0.03). In fact, subjects with dysplastic naevi
had higher relative odds for melanoma, but they did not
significantly vary by XPD status: when compared with subjects
without dysplastic naevi and with the 751Lys/Lys genotype,
individuals with dysplastic naevi and the 751Lys/Lys genotype
had OR¼10.9 (95% CI¼3.6–33.7); those with dysplastic naevi
and either the 751Gln/Lys or 751Gln/Gln genotype had OR¼6.7
(95% CI¼2.4–18.2). Among older subjects with dysplastic naevi,
the variant alleles had lower relative odds (OR¼2.3, 95%CI¼0.3–
18.4 for subjects with dysplastic naevi and 751Gln/Lys or 751Gln/
Gln genotype vs subjects with dysplastic naevi and 751Lys/Lys
genotype) than in subjects without dysplastic naevi. Odds ratios
for melanoma were not associated with the Lys751Gln polymorph-
ism among subjects younger than 50 years of age, independently of
their dysplastic naevus status.
Melanoma risk associated with the XPD 312Asn variant was not
increased (Table 2) and did not significantly vary by dysplastic
naevus status (P¼0.52).
Among subjects with low tanning ability, the XPD variant alleles
(Table 2) exhibited an increased risk for melanoma (OR¼2.3, 95%
CI¼0.7–7.0 for 312Asn; OR¼3.0, 95% CI¼1.0–8.8 for 751Gln).
In subjects with medium or high tanning ability, we observed no
association of melanoma risk with the 312Asn (OR¼1.3, 95%
CI¼0.7–2.4) or 751Gln (OR¼1.0, 95% CI¼0.6–1.8) variant.
However, the risk modification by tanning ability was not
statistically significant (PX0.08). Even though based on small
number of subjects, we found similar results after dividing the
subjects with low tanning ability in two groups with high or low
lifetime recreational sun exposure (data not shown).
XPD polymorphisms and DNA repair capacity
We evaluated whether global DNA repair capacity, measured
through the HCR assay, varied in subjects with different XPD
genotypes. DNA repair capacity exhibited a nonsignificant trend in
the association with the Lys751Gln polymorphism. The median
DNA repair capacity after 350Jm
 2 UV-irradiation was 19.5% in
subjects (n¼88) with the 751Lys/Lys genotype, 18.5% in subjects
(n¼144) with the 751Gln/Lys genotype, and 17.3% in subjects
(n¼45) with the 751Gln/Gln genotype (P¼0.55). No association
was present between Asp312Asn and DNA repair capacity. We
adjusted for cumulative hours of sun exposure during vacation,
repeated the analysis in cases, controls, and/or subgroups with
different age, dysplastic naevus status or tanning ability, and did
not find any significant correlation between Asp312Asn or
Lys751Gln and DNA repair capacity.
Table 2 XPD Asp312Asn and Lys751Gln polymorphisms and risk of cutaneous malignant melanoma in the overall analysis and by age, presence of
dysplastic naevi or tanning ability
XPD 312 XPD 751
Genotype Case Control OR
a (95% CI)
a Genotype Case Control OR
a (95% CI)
a
Overall analysis
Asp/Asp (G/G) 52 59 1.0 Ref. Lys/Lys (A/A) 58 59 1.0 Ref.
Asp/Asn (G/A)
Asn/Asn (A/A) 112 113 1.5
(0.9-2.5) Lys/Gln (A/C)
Gln/Gln (C/C) 118 118 1.3
(0.8–2.1)
By age (years)
17–49 Asp/Asp (G/G) 31 28 1.0 Ref. Lys/Lys (A/A) 34 30 1.0 Ref.
17–49
Asp/Asn (G/A)
Asn/Asn (A/A) 49 74 0.7
(0.4-1.5) Lys/Gln (A/C)
Gln/Gln (C/C) 51 75 0.7
(0.4–1.5)
50–77 Asp/Asp (G/G) 21 31 1.0 Ref. Lys/Lys (A/A) 24 29 1.0 Ref.
50–77
Asp/Asn (G/A)
Asn/Asn (A/A) 63 39 3.4
(1.6–7.3) Lys/Gln (A/C)
Gln/Gln (C/C) 67 43 2.3
(1.1–4.9)
Test of heterogeneity
of ORs
b
P¼0.004 P¼0.03
By presence of dysplastic navi
c
No Asp/Asp (G/G) 12 29 1.0 Ref. Lys/Lys (A/A) 9 33 1.0 Ref.
No
Asp/Asn (G/A)
Asn/Asn (A/A) 40 74 1.4
(0.6-3.2) Lys/Gln (A/C)
Gln/Gln (C/C) 46 72 2.6
(1.1–6.4)
Yes Asp/Asp (G/G) 23 11 1.0 Ref. Lys/Lys (A/A) 26 10 1.0 Ref.
Yes Asp/Asn (G/A)
Asn/Asn (A/A) 32 17 0.9
(0.3–2.4) Lys/Gln (A/C)
Gln/Gln (C/C) 33 19 0.6
(0.2–1.6)
Test of heterogeneity
of ORs
b
P¼0.52 P¼0.03
By tanning ability
High/medium Asp/Asp (G/G) 36 51 1.0 Ref. Lys/Lys (A/A) 41 47 1.0 Ref.
High/medium
Asp/Asn (G/A)
Asn/Asn (A/A) 67 92 1.3
(0.7–2.4) Lys/Gln (A/C)
Gln/Gln (C/C) 70 99 1.0
(0.6–1.8)
Low Asp/Asp (G/G) 15 8 1.0 Ref. Lys/Lys (A/A) 16 11 1.0 Ref.
Low
Asp/Asn (G/A)
Asn/Asn (A/A)
41 17 2.3 (0.7-7.0) Lys/Gln (A/C)
Gln/Gln (C/C)
44 15 3.0 (1.0-8.8)
Test of heterogeneity
of ORs
b
P=0.39 P=0.08
aOdds ratios (ORs) and 95% confidence intervals (95% CIs) adjusted for age, gender, dysplastic naevus status, skin colour, tanning ability and eye colour.
bLikelihood-ratio test for
interaction with XPD polymorphism.
cSubjects older than 60 years of age were considered as with uncertain dysplastic naevus status.
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Previous investigations in noncancer subjects with different ethnic
backgrounds reported variable frequencies of the 312Asn and
751Gln alleles (Goode et al, 2002). We found a high frequency of
the two XPD variants in this Italian population, as previously
described by other investigators (Matullo et al, 2001) for the
751Gln polymorphism.
Similar to our previous report on DNA repair capacity and
melanoma (Landi et al, 2002), we did not find a significant overall
association between melanoma risk and the XPD polymorphisms.
However, both 312Asn and 751Gln alleles were associated with
increased melanoma risk in subjects who were 50 years of age or
older. Recently, Hemminki et al (2001) showed that the Asp312Asn
and Lys751Gln polymorphisms might interact with age in their
association with repair rates of UV-induced lesions in the skin. In
the Hemminki’s study, subjects X50 years of age carrying the XPD
variants exhibited lower DNA repair.
To date, only two studies have investigated the association
between melanoma risk and XPD polymorphisms. A small study
that compared the results from 28 Stage I melanoma patients with
33 samples from healthy blood donors found an overrepresenta-
tion of the 751Lys allele among the melanoma cases (Tomescu et al,
2001). This first investigation that did not analyse the Asp312Asn
polymorphism was restricted to subjects younger than 50 years of
age. In our study, the proportion of the 751Lys/Lys genotype was
moderately higher among cases than controls in younger subjects
(Table 2). A second investigation conducted in 125 melanoma
cases and 211 cadaveric renal transplant donors failed to find an
association between Asp312Asn or Lys751Gln and melanoma
(Winsey et al, 2000). The median age of the cases was 52 years; the
age of the control group was not reported. No data on the
interaction between XPD variants and age or other risk factors
were provided in these two studies. Similar to our results, two
additional investigations on basal cell carcinoma (Dybdahl et al,
1999) and head and neck cancer (Sturgis et al, 2000) suggested that
carriers of the XPD 751Gln allele may be at risk for cancer at an
older age. None of the two studies evaluated the Asp312Asn
polymorphism.
Gilchrest et al (1999) suggested that age plays a major role in
vulnerability to photocarcinogens. Melanoma risk exhibits a steep
increase with age. In the study area, melanoma incidence rates,
which we calculated from available data (Parkin et al, 1997), were
equal to 6.1/100000 person-years in subjects between 15 and 49
years of age and 17.5/100000 person-years between 50 and 74
years. Cumulative DNA damage during aging is the result of errors
in DNA replication occurring at low but finite rate or of
incompletely repaired DNA damage (Yaar and Gilchrest, 2001).
As age increases, subjects accumulate more opportunities for DNA
damage due to prolonged exposure to UV radiation and other
carcinogens. Furthermore, defences against sunlight exposure,
such as skin pigmentation (Yaar and Gilchrest, 2001), epidermal
thickness (Yaar and Gilchrest, 2001), and DNA repair efficiency
(Wei et al, 1993; Yaar and Gilchrest, 1998) may decrease with age.
In older subjects, the equilibrium between DNA damage and repair
may be altered and further destabilised in presence of variant
alleles in DNA repair genes, which may be otherwise negligible.
The genetic alterations and the possible sequence of mutations
needed for the progression to melanoma are still to be defined.
Bennet (2003) recently proposed a speculative model for the
genetic basis of primary melanoma in relation to cell senescence.
In this model, early gene mutations leading to melanocyte
proliferation, such as those in the RAS, protein tyrosine kinase
or BRAF genes, are followed by lesions in the p16/RB1 pathway.
These alterations may be associated with the development of
common or dysplastic naevi and, eventually, with the radial growth
phase of malignant melanoma. Additional molecular events
possibly linked to apoptosis suppression, such as PTEN loss,
overexpression of a number of protein tyrosine kinases and RAS or
beta-catenin activation, could be required for the progression to
invasive melanoma. Further research is needed to assess how
variations in XPD and, in general, DNA repair function affect the
molecular events involved in melanoma development.
In a previous study on the same population, we showed an
interaction in the association with melanoma risk between the
overall DNA repair capacity, measured using the HCR assay, and
presence of dysplastic naevi or low tanning ability (Landi et al,
2002). In the present study, the effect of the XPD 751Gln allele was
evident in subjects without dysplastic naevi, particularly at older
age. Presence of dysplastic naevi did not appear to modify the
association between XPD Lys751Gln polymorphism and melanoma
risk in subjects younger than 50 years of age. The presence of
dysplastic naevi is one of the strongest risk factors for melanoma.
The association between dysplastic naevi and melanoma in our
population was also very strong (Landi et al, 2001) and this could
have overwhelmed the effect of XPD variants in older subjects with
dysplastic naevi. Caution is needed in the appraisal of these results
because the relatively small sample size limited the assessment of
the association between melanoma and XPD genotype when
subjects were categorised at the same time by dysplastic naevus
status and age. Naevi and dysplastic naevi tend to disappear with
age, making their diagnosis difficult to assess in older individuals
(Tucker et al, 1997). To be conservative, we classified all subjects
older than 60 years of age as of uncertain dysplastic naevus status.
However, the inclusion in the statistical analysis of the dysplastic
naevus diagnoses in older subjects did not change the results.
As for tanning ability, similar to what we found in the
association between DNA repair capacity and melanoma (Landi
et al, 2002), there was a nonsignificantly increased risk of
melanoma in subjects with both low tanning ability and a variant
genotype. Subjects with a low tanning ability may be at increased
risk of DNA damage, because they have lower protection against
UV-exposure. A less efficient DNA repair may increase melanoma
risk in these subjects.
We found a nonsignificant association between the overall DNA
repair capacity and Lys751Gln polymorphism. This finding is
consistent with previous investigations that measured DNA repair
capacity by the HCR assay on peripheral lymphocytes of healthy
subjects (Seker et al, 2001; Spitz et al, 2001) or on lymphoblastoid
cell lines (Qiao et al, 2002b). The sensitivity of the assay measuring
DNA repair capacity may have been a limiting factor in the
assessment of the association. A recent study using the HCR assay
based on the luciferase reporter gene found, as we did, significantly
lower levels of DNA repair capacity in 751Gln/Gln than in 751Lys/
Lys subjects, but in this case the association was statistically
significant (Qiao et al, 2002a).
In conclusion, the XPD 312Asn and 751Gln variant alleles were
associated with an increased risk for melanoma in subjects older
than 50 years of age. The presence of dysplastic naevi and low
tanning ability may also affect the association between XPD
polymorphisms and melanoma risk. As with all statistical
interactions that are identified for the first time, replication in
an independent study is necessary. Future studies, assessing
multiple genes involved in nucleotide excision repair, may help
evaluate the genetic basis of the interplay between DNA repair and
age or other host characteristics.
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